Abstract
Abstract
Background
Since late 2019, fortification of ‘regular’ cannabis plant material with synthetic cannabinoid receptor agonists (SCRAs) has become a notable phenomenon on the drug market. As many SCRAs pose a higher health risk than genuine cannabis, recognizing SCRA-adulterated cannabis is important from a harm reduction perspective. However, this is not always an easy task as adulterated cannabis may only be distinguished from genuine cannabis by dedicated, often expensive and time-consuming analytical techniques. In addition, the dynamic nature of the SCRA market renders identification of fortified samples a challenging task. Therefore, we established and applied an in vitro cannabinoid receptor 1 (CB1) activity-based procedure to screen plant material for the presence of SCRAs.
Methods
The assay principle relies on the functional complementation of a split-nanoluciferase following recruitment of β-arrestin 2 to activated CB1. A straightforward sample preparation, encompassing methanolic extraction and dilution, was optimized for plant matrices, including cannabis, spiked with 5 µg/mg of the SCRA CP55,940.
Results
The bioassay successfully detected all samples of a set (n = 24) of analytically confirmed authentic Spice products, additionally providing relevant information on the ‘strength’ of a preparation and whether different samples may have originated from separate batches or possibly the same production batch. Finally, the methodology was applied to assess the occurrence of SCRA adulteration in a large set (n = 252) of herbal materials collected at an international dance festival. This did not reveal any positives, i.e. there were no samples that yielded a relevant CB1 activation.
Conclusion
In summary, we established SCRA screening of herbal materials as a new application for the activity-based CB1 bioassay. The simplicity of the sample preparation, the rapid results and the universal character of the bioassay render it an effective and future-proof tool for evaluating herbal materials for the presence of SCRAs, which is relevant in the context of harm reduction.
Funder
The Bijzonder Onderzoeksfonds (BOF) of Ghent University
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. EMCDDA. Thematic papers: understanding the ‘Spice’ phenomenon. Luxembourg: Publications Office of the European Union; 2009.
2. EMCDDA. Synthetic cannabinoids in Europe - a review. Luxembourg: Publications Office of the European Union; 2021.
3. EMCDDA. New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU early warning system (June 2022). Luxembourg: Publications Office of the European Union; 2022.
4. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999;58:315–48.
5. Lapoint J, James L, Moran C, Nelson L, Hoffman R, Moran J. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila). 2011;49:760–4.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献